Basophil Activation Test

ApprovedBiologic

UUniversity Hospital, Rouen

Basophil Activation Test is one of 11 biologic programs targeting Food Allergy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Food AllergyActive, not recruiting

Food AllergyApproved

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Food Allergy

#DrugCompanyPhaseTrials

Calquence

Singulair

1 3

Xolair

Roche

Phase 3

5 4

Imbruvica

DUPIXENT

Ligelizumab

1 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

2 8

Basophil Activation Test

UUniversity Hospital, Rouen

Approved

1 9

Cibinqo

Pfizer

Phase 1

1 10

Epiceram

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Food Allergy1 trial

Basophil Activation Test (BAT) Sensitivity in Child Food Allergy

Completed·UUniversity Hospital, Rouen·Phase 4·NCT01966640·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Basophil Activation Test. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Basophil Activation Test compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Basophil Activation Test. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital, Rouen

Basophil Activation Test

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Food Allergy1 trial

References

Drug Info

Quick Facts

Related News